ADA/ADA mice) are impaired in regulation by calmodulin, develop severe cardiac hypertrophy and die about 2 weeks after birth. We hypothesized that the interleukin 6 (IL-6)/signal transducer and activator of transcription-3 (STAT3) signaling pathway has a role in the development of the Ryr2 ADA/ADA cardiac hypertrophy phenotype, and determined cardiac function and protein levels of IL-6, phosphorylation levels of STAT3, and downstream targets c-Fos and c-Myc in wild-type and RyR2 ADA/ADA mice, mice with a disrupted IL-6 gene, and mice treated with STAT3 inhibitor NSC74859. IL-6 protein levels were increased at postnatal day 1 but not day 10, whereas pSTAT3-Tyr705/STAT3 ratio and c-Fos and c-Myc protein levels increased in hearts of 10-day but not 1-day old Ryr2 ADA/ADA mice compared with wild type. Both STAT3 and pSTAT3-Tyr705 accumulated in the nuclear fraction of 10-day old Ryr2 ADA/ADA mice compared with wild type. Ryr2 ADA /ADA /IL-6 ¡/¡ mice lived 1.5 times longer, had decreased heart to body weight ratio, and reduced c-Fos and c-Myc protein levels. The STAT3 inhibitor NSC74859 prolonged life span by 1.3-fold, decreased heart to body weight ratio, increased cardiac performance, and decreased pSTAT-Tyr705/STAT3 ratio and IL-6, c-Fos and c-Myc protein levels of Ryr2 ADA /ADA mice. The results suggest that upregulation of IL-6 and STAT3 signaling contributes to cardiac hypertrophy and early death of mice with a dysfunctional ryanodine receptor. They further suggest that STAT3 inhibitors may be clinically useful agents in patients with altered Ca 2C handling in the heart.
INTRODUCTION
Type-2 ryanodine receptors (RyR2s) release Ca 2C from the sarcoplasmic reticulum (SR) to cause cardiac muscle contraction. The RyR2s are composed of 4 560-kDa RyR2 and 4 12.6-kDa FK506 binding protein subunits, and regulated by Ca 2C and associated proteins such as calmodulin (CaM). [1] [2] [3] [4] CaM is a 16.7-kDa Ca 2C binding protein that modulates proteins through CaM-dependent protein kinases and phosphatases or through direct binding. 5 In mouse cardiomyocytes, the majority of CaM is bound to RyR2 6 which reduces the release of Ca 2C from SR by inhibiting RyR2. [7] [8] [9] To determine the role of CaM in regulating RyR2 in vivo, a mouse model with 3 amino acid replacements in the CaM binding domain of RyR2 (RyR2-W3587A/L3591D/ F3603A, RyR2 ADA ) was generated. 10 The triple mutation impaired inhibition of RyR2 by CaM at diastolic and systolic Ca 2C , and resulted in severe cardiac hypertrophy and death of mice within about 2 weeks after birth. The mutations did not appear to introduce other major structural and functional changes in RyR2. The mutant mice had reduced RyR2 content and SERCA2a activity, lower Ca v 1.2 current density and showed irregularities in local and global Ca 2C transients. [10] [11] Ultrastructural analysis indicated only minor structural changes in myofibrillar organization, however, a reduction in SR/Ttubule junctions and RyR2 content were observed in mutant hearts which had a 2-3-fold increase in size compared to wild type. 12 Additionally, several signaling molecules were implicated in cardiac hypertrophy of Ryr2 ADA/ADA mice. Phosphorylation levels of extracellular signal-regulated kinases 1 and 2, p90 ribosomal S6 kinase and glycogen synthase kinases 3a and 3b increased in hearts of embryonic day 16.5 Ryr2 ADA/ADA mice. 13 Class II histone deacetylase/myocyte enhancer factor-2 signaling and nuclear factor of activated T cell transcriptional activity were up-regulated in the hearts from 1-day old Ryr2
ADA/ADA mice but not hearts from E16.5 mice. 10, 13 Calcineurin A-b ablation decreased heart weight and improved cardiac contractility and extended the lifespan of Ryr2 ADA/ADA mice by 2-fold, without suppressing the expression of genes associated with cardiac hypertrophy. 13 Treatment with rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), inhibited phosphorylation of mTOR and downstream targets ribosomal S6 kinase and ribosomal protein S6, decreased heart size, and improved cardiac function but did not extend the lifespan of Ryr2 ADA/ADA mice. 14 The results suggest that multiple signaling pathways are involved in the development of cardiac hypertrophy and heart failure in Ryr2 ADA/ADA mice expressing cardiac RyR2 impaired in regulation by CaM.
The present study explores the role of interleukin-6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) signaling in cardiac hypertrophy and heart failure in Ryr2 ADA/ADA mice. In addition to its wellknown role in inflammatory and immunological processes, increased circulating levels of IL-6 and related cytokines have been linked to heart failure in patients and animal models. 15 Binding of IL-6 to membrane-bound and soluble receptors results in a complex with glycoprotein (gp) 130. 15 In turn, formation of the IL-6/IL-6R/gp130 complex triggers 3 major downstream signaling pathways, janus kinase (JAK)/(STAT), mitogen activated protein kinase and phosphatidylinositol 3-kinase (PI3K)-AKT dependent pathways. 15, 16 Seven structurally related but functionally distinct isoforms of STAT 17 are e1158379-2expressed in cardiomyocytes. 18 Among these, STAT3 has been implicated in the development of cardiac hypertrophy. 15, [19] [20] [21] [22] [23] [24] Binding of IL-6 to its receptor and complex formation with gp130 causes phosphorylation of associated JAKs and recruitment and phosphorylation of STAT3. Following its phosphorylation, STAT3 translocates to the nucleus where it binds to response elements of c-Fos and c-Myc target genes. [25] [26] [27] Absence of a hypertrophic response in the absence of soluble IL-6 receptor 28 and dependence of STAT3 phosphorylation on the soluble receptor 29 suggested that Il-6 mediates its effect on STAT3 through the soluble receptor in cardiomyocytes.
Here we show that IL-6 protein levels, STAT3 phosphorylation, and c-Fos and c-Myc protein levels are upregulated in Ryr2 
STAT3 inhibitor treatment
STAT3 inhibitor NSC74859 was dissolved (1.5 mg/ml) in 0.15 M NaCl and 3% DMSO. 31 One day old mice were separated randomly into 4 groups. NSC74859 (20 mg/g body weight) was injected intraperitoneally once every day. Vehicle injection served as the negative control. For mRNA analysis, animals were sacrificed and hearts collected 1 h after the last injection. For protein analysis, hearts were collected 4 h after the final injection.
Echocardiography
To determine left ventricular cardiac function in mice, transthoracic M-mode echocardiography was performed on restrained unanesthetized 10-day old mice, using a 770 high resolution imaging system (VisualSonics) with a 40-MHz probe. Mice were restrained by taping down gently to on a warmed mouse board (Indus Industries for VisualSonics).
Quantitative RT-PCR
Total RNA was extracted from left ventricles of 10-day old mice using Trizol (Invitrogen) and reverse transcribed into cDNA using SuperScript First-Strand Synthesis System for RT-PCR Kit (Invitrogen). Real-Time PCR was performed using the following primers: IL-6, (s C for 10 min, and 40 cycles of 95 C for 15 sec and 60 C for 30 sec. Melting curve analysis of products was performed following each amplification to verify the specificity of the PCR products. 18S RNA was used as an internal control for normalization.
Preparations of heart fractions
Whole heart homogenates were prepared in 20 mM imidazole, pH 7.0, containing 0.3 M sucrose, 0.15 M NaCl, protease and phosphatase inhibitor cocktails, 25 mM b-glycerophosphate, 5 mM NaF, and 2.5 mM NaVO 4 using Tekmar Tissumizer for 3 £ 7 s at a setting of 13,500 rpm. Cytosolic and nuclear fractions were prepared using Pierce Biotechnology NePer Nuclear and Cytoplasmic Extraction Reagents kit. Cellular fractions were stored in small aliquots at ¡80 C. Protein concentrations were determined using the bicinchoninic acid assay.
Immunoblot analysis
Homogenates (20 mg protein/lane) were separated by 10% SDS/PAGE, transferred to nitrocellulose membranes, and probed with monoclonal or polyclonal antibodies. Western blots were developed using enhanced chemiluminescence and quantified using ImageQuantTL Analysis Software. GAPDH was the loading control.
Statistical analysis
Statistical analysis was performed using Sigma-plot 11. T-test was used to compare 2 groups and ANOVA followed by Tukey's test to analyze the significance among multi groups. Statistical significance was taken at the p < 0.05 level.
RESULTS
Upregulation of IL-6 and pSTAT3-Tyr-705 in Ryr2 ADA/ADA mouse hearts
We reported previously that mice with impaired CaM inhibition of the cardiac ryanodine receptor (Ryr2 ADA/ADA mice) show signs of cardiac hypertrophy at postnatal day 1 and die within about 2 weeks after birth. 10 To determine the mechanism of cardiac hypertrophy induced by the RyR2 mutation, protein levels of IL-6 and STAT3, phosphorylation levels of pSTAT3-Tyr705 and pSTAT3-Tyr727, and protein levels of c-Fos and c-Myc downstream transcription factors were determined. An increase in IL-6 protein was observed in 1-day old but not 10-day old Ryr2 ADA/ADA hearts, whereas STAT3 protein levels were similar in e1158379- 4 Huang et al.
wild-type Ryr2 C/C hearts ( Fig. 1) . STAT3 is activated by phosphorylation at Tyr-705 following phosphorylation of janus kinase (JAK) in IL-6/IL-6R/p130-JAK complex, whereas phosphorylation at Ser-727 is mediated through the mitogen activated protein kinase and mTOR pathways. 15 The pSTAT3-Tyr705/ STAT3 ratio increased at postnatal day 10, but not at postnatal day 1 (Fig. 1) or days 3-4 (not shown). No change in the pSTAT3-Ser727/ STAT3 ratio was observed at postnatal days 1 and 10. Consistent with the absence of an elevated pSTAT3-Tyr705/STAT3 ratio at postnatal days 1 and 3-4, c-Fos and c-Myc increased only during the later stages of cardiac hypertrophy compared to wild-type hearts (Fig. 1) . The data suggested the IL-6/STAT3 signaling pathway may have a role in development of the Ryr2 ADA/ADA cardiac hypertrophy phenotype.
To determine whether STAT3 and phosphorylated pSTAT3-Tyr705 translocated to the nucleus in hearts of Ryr2 ADA/ADA mice, cytosolic and nuclear fractions were prepared. GAPDH and histone 3 served as cytosolic and nuclear markers, respectively (Fig. 2) . In agreement with the nuclear accumulation of unphosphorylated STAT3 in response to IL-6, 32 STAT3 was enriched in the nuclear fraction of 10-day old Ryr2 ADA/ADA hearts. C/C, # p < 0.05 compared to corresponding 1 day sample using one way ANOVA.
IL-6/STAT3 SIGNALING IN RYR2
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pSTAT-Tyr705 was predominantly localized in the nuclear fraction of Ryr2 ADA/ADA mouse hearts compared to wild-type hearts.
Ryr2 ADA/ADA /IL-6 ¡/¡ mice. In addition to IL-6, other members of the cytokine family might have contributed to the Ryr2 ADA/ADA cardiac hypertrophy phenotype. 15 To obtain evidence that IL-6 signaling was associated with cardiac hypertrophy, we generated ¡/¡ mice carrying an IL-6 gene disrupted in the first coding exon by insertion of neo cassette 33 were viable without change in body to heart weight ratio compared with Ryr2 C/C mice ( (Fig. 3) .
Echocardiography indicated that the IL-6 mutation did not significantly alter cardiac performance in Ryr2 C/C and Ryr2 ADA/ADA mice ( Table 1) . Co-expression of Ryr2 ADA/ADA and IL-6 mutants did not alter STAT3 protein levels and pSTAT-Ser-727/STAT3 ratios among the 4 genotypes (Fig. 4) . The elevated pSTAT3-Tyr705/ STAT3 ratio in the hearts of Ryr2 ADA/ADA mice was modestly (not significant) decreased in the mutant mice carrying the IL-6 mutation, whereas the IL-6 mutant significantly decreased c-Fos and c-Myc protein levels in Ryr2 ADA/ADA mice. No significant change was observed in Ryr2 C/C /Il-6 ¡/¡ mice compared with Ryr2 C/C mice (Fig. 4) . Taken together, the results of Figure 4 and Table 1 suggest that IL-6 had a role in decreasing lifespan, increasing heart size and upregulating c-Fos and c-Myc protein levels in Ryr2 ADA/ADA mice. However, the data also suggest that other mechanisms exist that contributed to the Ryr2 ADA/ADA phenotype.
Treatment with STAT3 inhibitor NSC74859
To obtain more direct evidence for STAT3 regulation in cardiac hypertrophy of Ryr2 ADA/ADA mice, newborn mice were daily were markers for cytosolic and nuclear fractions, respectively. (B) Protein and phosphorylation levels of Ryr2 ADA/ADA mice were normalized to Ryr2 C/C . Data are the mean § SEM of 5-6 samples.*p < 0.05 compared to Ryr2 C/C using t-test.
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injected with specific STAT3 inhibitor NSC74859. 34 Treatment with NSC74859 significantly decreased the heart to body weight ratio in Ryr2 ADA/ADA mice compared to no change in Ryr2 C/C mice. The lifespan of Ryr2 ADA/ADA mice increased, with mean lifetimes of 18.4 § 1.8 d and 13.9 § 0.5 d with or without NSC74859 (p < 0.05), respectively (Fig. 5) 
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Treatment with NSC74859 significantly lowered IL-6 protein levels in both Ryr2 C/C and Ryr2 ADA/ADA hearts (Fig. 6) . The pSTAT3-Tyr705/STAT3 ratio and the protein levels of c-Fos and c-Myc in Ryr2 ADA/ADA mice were significantly reduced by NSC74859 without a change in Ryr2 C/C mice. The results show that the Ryr2 ADA/ADA phenotype is linked to elevated phosphorylation of pSTAT3 at Tyr-705 and protein levels of c-Myc and c-Fos.
Next we asked whether NSC74859 altered the mRNA levels of other cardiac hypertrophy associated genes. Quantitative RT-PCR showed that c-Fos and c-Myc mRNA levels increased in hearts from 10-day old Ryr2 ADA/ ADA mice compared with Ryr2 C/C mice.
NSC74859 decreased 5-fold c-Fos mRNA levels in Ryr2 ADA/ADA hearts without changing the levels in Ryr2 C/C mice (Fig. 7) . cMyc mRNA levels were not significantly reduced in the mutant mice. In agreement with our previous report, 10 brain (BNP) and atrial (ANP) natriuretic peptide mRNA levels were significantly increased in hearts from Ryr2 ADA/ADA mice compared to Ryr2 C/C mice. Interestingly, mRNA levels of cardiac hypertrophy associated genes BNP and ANP were not reduced by NSC74859 in hearts from Ryr2 ADA/ADA mice. Indeed, in the case of ANP, NSC74859 increased rather than decreased the mRNA level in Ryr2 ADA/ADA mice. The results suggest that, in addition to (ADA) mice with and without IL-6. GAPDH was the loading control. (B) Protein levels and phosphorylation ratios of Ryr2 ADA/ADA mice were normalized to Ryr2 C/C . Data are the mean § SEM of 6-14 determinations. p < 0.05 compared with Ryr2 C/C, # p < 0.05 compared with Ryr2 ADA/ADA , using one way ANOVA.
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IL-6/STAT3 signaling, other mechanisms are associated with the Ryr2 ADA/ADA phenotype.
DISCUSSION
Our findings suggest that aberrant Ca 2C handling in Ryr2 ADA/ADA mice increases IL-6 expression and activation of STAT3 through Tyr-705 phosphorylation. IL-6 is released by various tissues including heart and is synthesized in fibroblasts and cardiomyocytes. 35 Elevation of IL-6 by chronic infusion was associated with left ventricular hypertrophy, fibrosis, and dysfunction, 36 overexpression of both IL-6 and IL-6 receptor developed myocardial hypertrophy, 28 and cardiac hypertrophy induced by angiotensin II infusion was attenuated by deletion of IL-6. 37 On the other hand, deletion of IL-6 did not attenuate left ventricular remodeling or dysfunction in pressure-overloaded hearts. 38 We find that IL-6 protein levels increased in 1-day old but not in 10-day old Ryr2
ADA/ADA mice. Ryr2
mice carrying a disrupted IL-6 gene lived longer and had a decreased heart size without significantly altered cardiac performance. In addition, loss of IL-6 decreased protein levels of c-Fos and c-Myc, 2 STAT3-responsive transcription factors 25, 27 that are rapidly induced in the ventricular myocardium by pressure overload. 39 To obtain evidence that IL-6 mediated its effects through phosphorylation of STAT3 at Tyr-705, Ryr2
ADA/ADA mice were treated with the STAT3 inhibitor NSC74859 (S3I-201). NSC74859 interacted with the STAT3 SH2 domain and preferentially inhibited growth in cells that contained STAT3 activated by phosphorylation at Tyr-705 by inhibiting STAT3 ADA/ADA mice without NSC74859, using one way ANOVA.
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dimer formation and STAT3 DNA-binding and transcriptional activities. 34 NSC74859 was effective in inhibiting angiotensin-II induced oxidative stress, endothelial dysfunction and hypertension in 4-5 month old mice 40 and in decreasing heart size, improving cardiac function and inhibiting cardiac hypertrophy markers such as ANP, c-Fos and c-Myc in a renal artery ligated rat model. 26 In the present study, in agreement with the results from the rat model, 26 daily injection of NSC74859 significantly increased lifespan and decreased c-Fos and c-Myc protein levels in Ryr2 ADA/ADA / Il-6 ¡/¡ mice. However, at variance with ANP expression at the protein level in the renal artery ligated rat model, 26 ANP mRNA expression was increased in Ryr2 ADA/ADA by NSC74859 without a change in Ryr2 C/C mice. Thus the pathological effects of the RyR2 ADA mutation appear to be mediated in part by additional mechanisms that may include an upregulation of calcineurin A-b 13 and mTOR 14 signaling. Another possibility is that nuclear accumulation of unphosphorylated STAT3 contributed to the Ryr2 ADA/ADA phenotype. NSC74859 was less effective in reducing growth and viability in normal fibroblast NIH3T3 cells than transformed NIH3T3 cells that harbored activated pSTAT3-Tyr705, 34 which suggests that nuclear STAT3 may promote the activation of genes that do not respond directly to phosphorylated STAT3. 41 An intriguing result from our studies was evidence that STAT3 inhibition by NSC74859 reduced the IL-6 protein level in hearts of Ryr2 C/C and Ryr2 ADA/ADA mice. This could suggest at first sight that the effects of NSC74859 are due to its direct effect on IL-6 expression. However, this appears unlikely, as there is no evidence of a direct interaction with Il-6. More likely, NSC74859 inhibited Il-6 expression by inhibiting STAT3 transcriptional activity. 34 Myocardial IL-6 expression is regulated by multiple factors. Hypoxia-induced activation of IL-6 was mediated by transcriptional factors NF-IL-6 and NF-k B in primary cultures of myocytes prepared from 1-day old rat hearts. 42 In skeletal muscle, activator protein-1, NF-k B and inositol trisphosphate release of Ca 2C were involved in upregulation of IL-6 transcription. 43 In 8-week old mouse hearts, STAT1 promoted the expression of IL-6 and countered the suppressive role of p53. 44 In adult rat ventricular myocytes, IL-1 and b-adrenergic receptor synergistically increased IL-6 expression and secretion. 29 Further, C/C mice with NSC74859, using one way ANOVA.
coordinate regulation of STAT3 and microRNAs suggests that IL-6 expression was regulated by microRNAs. 45 Future studies will be required to clarify the relationship between the effects of NSC74859 on STAT3 signaling and suppression of IL-6 expression in the hearts of young Ryr2 ADA/ADA mice. In summary, our results indicate that impaired inhibition of RyR2 by CaM resulted in increased IL-6 expression, phosphorylation of STAT3 at Tyr-705, and nuclear accumulation of both phosphorylated and unphosphorylated STAT3. Generation of double targeted Ryr2 ADA/ADA /IL-6 ¡/¡ mice and treatment of Ryr2 ADA/ADA mice with STAT3 inhibitor NSC74859 prolonged life span, decreased heart size, and decreased the expression levels of proteins associated with IL-6/STAT3 signaling. The results suggest that upregulation of IL-6 and STAT3 signaling contribute to the rapid development of cardiac hypertrophy and early death of Ryr2 ADA/ADA mice.
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